The Department of Diagnostics offers a value chain that comprises the screening and testing of biomarkers, bioinformatic analysis and interpretation of complex transcriptome and genome data (”big data”), development of in vitro diagnostics (IVD) and point-of-care platforms as well as appropriate preclinical animal models.
Within the department, the RIBOLUTION Biomarker Center was established in the course of the FraunhoferZukunftsstiftung- (Future Foundation-) funded consortium RIBOLUTION (RIBOnucleic acid-based diagnostic soLUTIONs) to systematically identify and validate novel diagnostic or prognostic biomarkers. Noncoding RNAs that possess a promising and long underestimated biomarker potential are a particular focus. The RIBOLUTION Biomarker Center provides experienced bioinformatics for analyzing NGS and other complex data sets. Competencies in study and data management serve to design and conduct clinical cohorts as well as to manage clinical and experimental data. For the development of diagnostic assays, a quality management system following DIN EN ISO13485 rules has been implemented.
The development of innovative molecular diagnostic test systems is offered for medical and food applications and comprises PCR- and NGS-based IVDs, lab-on-a-chipplatforms, and strip-based flash tests. The department aims at diagnostic solutions in many clinical fields, including cancer, infectious and inflammatory diseases.
It also offers the development of companion diagnostics and provides many established cell and animal models in various areas like tumor stem cells, rheumatoid arthritis and other chronic-inflammtory diseases as well as many more. Furthermore, xenogene transplantation models serve to close the gap between model and patient.